Aldeyra Therapeutics (ALDX) Interest & Investment Income (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 13 years of Interest & Investment Income data on file, last reported at $562977.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 42.64% year-over-year to $562977.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 45.83% YoY) and the FY2025 annual result came in at $3.3 million, down 46.32% from the prior year.
• Interest & Investment Income slipped to $562977.0 in Q1 2026, from $681635.0 in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $1.9 million in Q3 2023 to a low of $101382.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1904.52% — and 2025, when it slumped 47.55%.
• Tracing ALDX's Interest & Investment Income over 5 years: stood at $1.3 million in 2022, then soared by 48.08% to $1.9 million in 2023, then sank by 33.31% to $1.2 million in 2024, then tumbled by 45.02% to $681635.0 in 2025, then declined by 17.41% to $562977.0 in 2026.
• The last three Interest & Investment Income figures came in at $562977.0 (Q1 2026), $681635.0 (Q4 2025), and $788694.0 (Q3 2025), per Business Quant data.